FINWIRES · TerminalLIVE
FINWIRES

Amcor Estimates Cut Again on Higher Resin Costs, Softer Demand, Jefferies Says

By

Amcor (ASX:AMC) has had its earnings estimates cut by Jefferies for the second time in a month, as higher resin costs and softer consumer demand weigh on margins and cash flow, the firm said in a Thursday note.

Jefferies noted resin costs rose around 15% to 25% year on year, with the company's polyethylene and polypropylene input exposure at $5 billion to $6 billion annually, and expects the delayed impact of higher costs to pass through in coming quarters, resulting in a notable margin squeeze in the fourth quarter.

The firm expects fiscal 2026 earnings of about $3.94, below both company guidance of $4 to $4.15 and consensus at $4, and has cut fiscal 2027 estimates by around 4% on a more cautious view of demand and margins.

The firm highlighted working capital pressure, with an estimated $200 million drag from higher resin costs pushing fiscal 2026 leverage to around 3.5 times, and noted that a further 10% rise in resin prices could add around 0.4 times to leverage if fully passed through working capital.

The firm expects third quarter earnings before interest, taxes, depreciation and amortization of $936 million, in line with consensus, and earnings of $0.927, slightly below estimates due to higher interest costs, alongside low-single-digit volume declines and continued softness in food and household.

Jefferies kept a buy rating on Amcor and cut its price target to AU$71.83 from AU$75.27.

Related Articles

Asia

Netwealth's FUA Net Flows in Fiscal Q4 Likely to See Seasonal Step-up, Jarden Says

Netwealth Group's (ASX:NWL) funds under administration (FUA) net flows are likely to see a seasonal step-up in the fiscal fourth quarter, which would see the fiscal 2026 outcome tracking slightly ahead of its guidance range, Jarden said in a Thursday note.It raised its earnings-per-share forecasts by 0.1% for fiscal 2026, 1.5% for fiscal 2027, and 1.6% for fiscal 2028.Jarden also flagged the risk of higher cost growth due to the enforceable undertaking, regulatory scrutiny, and recent treasury consultations.The investment firm retained its neutral recommendation on Netwealth Group and raised the price target to AU$25.70 from AU$25.35.Netwealth Group's shares gained 1% in recent Friday trade.

ASX:NWL
Asia

CDL Hospitality REIT Issues Stapled Securities as Payment of Management Fee

CDL Hospitality REIT (SGX:J85) issued 5.5 million stapled securities to its manager, H-REIT Manager and HBT Trustee-Manager as payment of management fee for 2025, according to a Friday filing with the Singapore Exchange.Nearly 5 million stapled securities were issued to the H-REIT Manager at SG$0.8199 per security as 80% payment of its performance fee for 2025.Meanwhile, 535,179 securities were issued to HBT Trustee-Manager at SG$0.8199 per security as payment of 80% of performance fee for 2025.

SGX:J85
Asia

Syntara's Myelofibrosis Drug Candidate Shows 'Significant' Commercial Potential, Euroz Hartleys Says

Syntara's (ASX:SNT) Amsulostat drug candidate has a "unique" position in the myelofibrosis landscape and "significant" commercial potential, Euroz Hartleys said in a Thursday note.Myelofibrosis is a blood cancer characterized by scar tissue formation or fibrosis in the bone marrow.Dr Adam Craig, Syntara strategic adviser and an industry leader in myelofibrosis, noted Amsulostat's mechanism targeting fibrosis, with the potential as a disease-modifying therapy, rather than just a symptomatic treatment.Craig said that Amsulostat's safety profile differs from current therapies and is unaware of any other drug taking a similar approach.Additionally, Craig said that Amsulostat's mechanism requires time for effect, as fibrosis evolves gradually. Patient responses observed at six months are complemented by a continuing improvement over time.Euroz Hartleys reaffirmed its speculative buy recommendation and AU$0.22 price target on Syntara.Syntara shares fell 1% in afternoon trade on Friday.

ASX:SNT